On February 17, 2022 Blue Water Vaccines, Inc. ("BWV" or "Blue Water Vaccines" or the "Company"), a biopharmaceutical company developing vaccines, reported the pricing of its initial public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share (Press release, Onconetix, FEB 17, 2022, View Source [SID1234641103]). The shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol "BWV" on February 18, 2022.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The aggregate gross proceeds to BWV from the initial public offering are expected to be approximately $20 million prior to deducting underwriting discounts, commissions, and other estimated offering expenses. The offering is expected to close on February 23, 2022, subject to the satisfaction of customary closing conditions.
Boustead Securities, LLC is acting as the sole book-running manager for the offering.
The Securities and Exchange Commission ("SEC") declared effective a registration statement on Form S-1 relating to these securities on February 11, 2022. A final prospectus relating to this offering will be filed with the SEC. The offering is being made only by means of a prospectus, copies of which, when available, may be obtained from; Boustead Securities, LLC, Attention: Prospectus Department, 6 Venture, Suite 325, Irvine, CA 92618, or by telephone at 949-502-4408, or by email at [email protected]. Investors may also obtain these documents at no cost by visiting the SEC’s website at View Source
Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.